Literature DB >> 9309701

Mitochondrial intermembrane inclusion bodies: the common denominator between human mitochondrial myopathies and creatine depletion, due to impairment of cellular energetics.

E O'Gorman1, T Piendl, M Müller, D Brdiczka, T Wallimann.   

Abstract

Mitochondrial inclusion bodies are often described in skeletal muscle of patients suffering diseases termed mitochondrial myopathies. A major component of these structures was discovered as being mitochondrial creatine kinase. Similar creatine kinase enriched inclusion bodies in the mitochondria of creatine depleted adult rat cardiomyocytes have been demonstrated. Structurally similar inclusion bodies are observed in mitochondria of ischemic and creatine depleted rat skeletal muscle. This paper describes the various methods for inducing mitochondrial inclusion bodies in rodent skeletal muscle, and compares their effects on muscle metabolism to the metabolic defects of mitochondrial myopathy muscle. We fed rats with a creatine analogue guanidino propionic acid and checked their solei for mitochondrial inclusion bodies, with the electron microscope. The activity of creatine kinase was analysed by measuring creatine stimulated oxidative phosphorylation in soleus skinned fibres using an oxygen electrode. The guanidino propionic acid-rat soleus mitochondria displayed no creatine stimulation, whereas control soleus did, even though the GPA solei had a five fold increase in creatine kinase protein per mitochondrial protein. The significance of these results in light of their relevance to human mitochondrial myopathies and the importance of altered cell energetics and metabolism in the formation of these crystalline structures are discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9309701

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  28 in total

1.  A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study.

Authors:  R LUFT; D IKKOS; G PALMIERI; L ERNSTER; B AFZELIUS
Journal:  J Clin Invest       Date:  1962-09       Impact factor: 14.808

2.  Structure of mitochondrial creatine kinase.

Authors:  K Fritz-Wolf; T Schnyder; T Wallimann; W Kabsch
Journal:  Nature       Date:  1996-05-23       Impact factor: 49.962

3.  Experimental ischemic myopathy.

Authors:  G Karpati; S Carpenter; C Melmed; A A Eisen
Journal:  J Neurol Sci       Date:  1974-09       Impact factor: 3.181

4.  Mitochondrial myopathy in rats fed with a diet containing beta-guanidine propionic acid, an inhibitor of creatine entry in muscle cells.

Authors:  Z Gori; V De Tata; M Pollera; E Bergamini
Journal:  Br J Exp Pathol       Date:  1988-10

5.  Creatine treatment in MELAS.

Authors:  L Hagenfeldt; U von Döbeln; G Solders; L Kaijser
Journal:  Muscle Nerve       Date:  1994-10       Impact factor: 3.217

6.  Differential effects of creatine depletion on the regulation of enzyme activities and on creatine-stimulated mitochondrial respiration in skeletal muscle, heart, and brain.

Authors:  E O'Gorman; G Beutner; T Wallimann; D Brdiczka
Journal:  Biochim Biophys Acta       Date:  1996-09-12

7.  Native mitochondrial creatine kinase forms octameric structures. I. Isolation of two interconvertible mitochondrial creatine kinase forms, dimeric and octameric mitochondrial creatine kinase: characterization, localization, and structure-function relationships.

Authors:  J Schlegel; B Zurbriggen; G Wegmann; M Wyss; H M Eppenberger; T Wallimann
Journal:  J Biol Chem       Date:  1988-11-15       Impact factor: 5.157

8.  Biochemical adaptation in the skeletal muscle of rats depleted of creatine with the substrate analogue beta-guanidinopropionic acid.

Authors:  E A Shoubridge; R A Challiss; D J Hayes; G K Radda
Journal:  Biochem J       Date:  1985-11-15       Impact factor: 3.857

9.  Intramitochondrial inclusions caused by depletion of creatine in rat skeletal muscles.

Authors:  Y Ohira; M Kanzaki; C S Chen
Journal:  Jpn J Physiol       Date:  1988

10.  Adult rat cardiomyocytes cultured in creatine-deficient medium display large mitochondria with paracrystalline inclusions, enriched for creatine kinase.

Authors:  M Eppenberger-Eberhardt; I Riesinger; M Messerli; P Schwarb; M Müller; H M Eppenberger; T Wallimann
Journal:  J Cell Biol       Date:  1991-04       Impact factor: 10.539

View more
  6 in total

Review 1.  Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases.

Authors:  Peter J Adhihetty; M Flint Beal
Journal:  Neuromolecular Med       Date:  2008-11-13       Impact factor: 3.843

2.  Stimulation of mitochondrial gene expression and proliferation of mitochondria following impairment of cellular energy transfer by inhibition of the phosphocreatine circuit in rat hearts.

Authors:  R J Wiesner; T V Hornung; J D Garman; D A Clayton; E O'Gorman; T Wallimann
Journal:  J Bioenerg Biomembr       Date:  1999-12       Impact factor: 2.945

Review 3.  The creatine kinase system and pleiotropic effects of creatine.

Authors:  Theo Wallimann; Malgorzata Tokarska-Schlattner; Uwe Schlattner
Journal:  Amino Acids       Date:  2011-03-30       Impact factor: 3.520

Review 4.  In vivo NMR studies of neurodegenerative diseases in transgenic and rodent models.

Authors:  In-Young Choi; Sang-Pil Lee; David N Guilfoyle; Joseph A Helpern
Journal:  Neurochem Res       Date:  2003-07       Impact factor: 3.996

5.  Creatine supplementation in health and disease. Effects of chronic creatine ingestion in vivo: down-regulation of the expression of creatine transporter isoforms in skeletal muscle.

Authors:  M L Guerrero-Ontiveros; T Wallimann
Journal:  Mol Cell Biochem       Date:  1998-07       Impact factor: 3.396

Review 6.  Distinct Mitochondrial Pathologies Caused by Mutations of the Proximal Tubular Enzymes EHHADH and GATM.

Authors:  Anna-Lena Forst; Markus Reichold; Robert Kleta; Richard Warth
Journal:  Front Physiol       Date:  2021-07-19       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.